NF-kB Inhibitor Therapy for Uterine Fibroid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for uterine fibroids often have side effects and are not suitable for long-term use, particularly those affecting estrogen/progesterone levels, and there is a need for safe, estrogen/progesterone-neutral therapies that effectively manage fibroid symptoms.
Innovation Solution
Administering the nuclear factor-kappa B (NF-kB) inhibitor, Bay 11-7082, to treat uterine fibroids by inhibiting the expression of pro-inflammatory genes and reducing fibroid growth, which is well-tolerated and effective in reducing tumor weight and ECM accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If gonadotropin-releasing hormone agonists are used to decrease fibroid size, then fibroid size is reduced, but side effects and cost increase
Solution Approach 1:
The patent extracts and targets the specific inflammatory pathway (NF-κB) that drives fibroid growth, separating this mechanism from hormonal pathways. By using NF-κB inhibitors instead of gonadotropin-releasing hormone agonists, the treatment reduces fibroid size through anti-inflammatory mechanisms while avoiding the side effects associated with hormonal manipulation.
Solution Approach 2:
The patent changes the therapeutic parameter from hormonal modulation to inflammatory pathway inhibition. By targeting NF-κB signaling and its downstream effects on cytokine production and cell proliferation, the treatment achieves fibroid reduction through a different physiological parameter (inflammation) rather than hormone levels, thereby avoiding hormonal side effects.
2Productivity
If estrogen/progesterone reducing therapies are used to treat fibroids, then fibroid growth is inhibited, but long-term use is not suitable due to side effects
Solution Approach 1:
The patent extracts the inflammatory component (NF-κB pathway) from the complex hormonal-regulated fibroid growth mechanism. By targeting this specific extracted pathway with NF-κB inhibitors, the treatment achieves sustained fibroid growth inhibition without the systemic hormonal side effects that limit long-term therapy with traditional estrogen/progesterone reducing agents.
Solution Approach 2:
The patent employs small molecule NF-κB inhibitors that can be administered orally or systemically, replacing the need for long-term hormonal therapies. These inhibitors provide a more sustainable treatment option with fewer cumulative side effects, enabling longer duration therapy compared to traditional hormonal approaches.
3Object-affected harmful factors
If surgery is performed to remove fibroids, then symptoms are relieved, but invasive procedures and recovery time increase
Solution Approach 1:
The patent replaces the mechanical surgical approach with a pharmacological approach. By using NF-κB inhibitors to systematically reduce fibroid size through inhibition of inflammatory pathways and cell proliferation, the treatment achieves symptom relief without the mechanical trauma, bleeding, and recovery time associated with surgical fibroid removal.
Solution Approach 2:
The patent introduces NF-κB inhibitors as an intermediary substance that mediates the reduction of fibroid size. Rather than directly removing fibroids through surgery, the inhibitors act as intermediaries that block the inflammatory signaling pathways driving fibroid growth, allowing the body to naturally reduce fibroid size over time without invasive intervention.
Data Source
AI summary
Methods of treating a subject for fibroid(s) are provided. Aspects of the methods include administering to the subject a nuclear factor-kappa B (NF-kB) inhibitor, e.g., Bay 11-7082, to treat the subject for fibroid(s). Also provided are compositions for use in practicing methods of the invention.